Monday, September 28, 2026
BTC $83,162 ▼ 0.36%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.246down−0.32%ETH$2,678down−0.37%LINK$15.42down−0.17%SOL$118.13down−0.59%BTC$83,162down−0.36%XRP$1.49down−0.40%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,148.00down−0.49%SILVER$60.96down−1.24%OIL$93.35up+0.81%DXY101.24up+0.05%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — GreedADA$0.246down−0.32%ETH$2,678down−0.37%LINK$15.42down−0.17%SOL$118.13down−0.59%BTC$83,162down−0.36%XRP$1.49down−0.40%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,148.00down−0.49%SILVER$60.96down−1.24%OIL$93.35up+0.81%DXY101.24up+0.05%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — Greed
Tag

keytruda

1 article

Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Research & Analysis40d ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.